Figure 6.

LAP expressing myeloid cell subsets are modulated in glioma patients

(A and B) Expression of LAP on MDSCs derived from glioma patients (n = 6–18). Representative flow cytometry dot plots including fluorescence minus one (FMO-LAP) controls and gating strategy (A) and quantification of cell frequencies (B) are shown.

(C and D) LAP expression on MHCII⁺ cells in glioblastoma patients (GBM) and healthy donors (HC) (n = 18). Representative flow cytometry dot plots including FMO controls (C) and quantification of cell frequencies (D) are shown.

(E) Changes in MHCII⁻ and MHCII⁺ MCs expressing LAP in the blood of GBM patients (n = 18). Frequencies of LAP expressing MHCII⁻ and MHCII⁺ MCs in GBM patients and healthy controls are shown.

(F) CCR2 expression on LAP⁺MHCII⁺ MCs. Representative flow cytometry dot plots in two GBM patients and a healthy donor (HC), including FMO-LAP control are shown.

(G) Percent survival of patients with relatively high or low mRNA expression of indicated genes, including MHCII (HLA-DPB1), combined expression of MHCII and LAP genes (HLA-DPB1/TGFB1) and PD-L1, MHCII and LAP (CD274/HLA-DPB1/TGFB1) in the tumor tissue of glioma patients (low grade glioma, LGG and GBM). Graphs and p values were downloaded from the TCGA dataset via cBioPortal (https://www.cbioportal.org; (Cerami et al., 2012; Gao et al., 2013)).

(H) Correlation between TGFB1 and HLA-DPB1, TGFB1 and CD274, HLA-DPB1 and CD274 expression in the tumor tissue of GBM patients. Graphs and p values were downloaded from TCGA dataset via cBioPortal (Cerami et al., 2012; Gao et al., 2013). Data shown as mean ± SEM. Mann-Whitney test (B) and two-tailed t test (D and E) were used for p value calculations. ∗∗∗∗, p < 0.0001. See also Figure S6.